Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary obtains registration certificate for Levocarnitine Injection drug.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its controlling subsidiary Guoyao Yixin Pharmaceutical Co., Ltd. (referred to as Guoyao Yixin) has received the "Drug Registration Certificate" for Levocarnitine Injection issued by the National Medical Products Administration. Levocarnitine Injection is suitable for chronic renal failure patients undergoing long-term hemodialysis who develop a series of complications due to secondary carnitine deficiency, with clinical manifestations such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, low blood pressure, muscle spasms during dialysis, and other symptoms.